Portal de Periódicos da CAPES

Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia

2011; Wiley; Volume: 71; Issue: 15 Linguagem: Inglês

10.1002/pros.21387

1097-0045

G. Robert, Frank Smit, Daphne Hessels, Sander A. Jannink, Herbert F.M. Karthaus, Tilly Aalders, Kees Jansen, Alexandre de la Taille, Peter F.A. Mulders, Jack A. Schalken,

Inflammatory mediators and NSAID effects

Abstract BACKGROUND Chronic prostatic inflammation could be a central mechanism in benign prostatic hyperplasia (BPH) progression. Currently, the histological examination of prostate biopsies remains the only way to diagnose prostatic inflammation. Our objective was to find new noninvasive biomarkers for the diagnosis of prostatic inflammation. METHODS Ninety BPH samples were investigated in two steps. First, a hypothesis was generated using a profiling procedure with a panel of 96 genes on an initial set of 30 samples. Then, the candidate biomarkers were validated on a large number of samples (n = 90). Gene expression was compared with the histological prostatic inflammation score based on the density and the confluence of lymphoid nodules. Finally, protein transcripts of the candidate biomarkers were investigated in urine samples and compared with clinical data. RESULTS Of the 96 genes, nine were significantly correlated with the inflammation score on the initial set of patients. Four of them were validated on the complete set of patients: CCR7, CD40LG, CTLA4, and ICOS. ICOS and CTLA4 protein levels were readily measured in urine samples using a conventional ELISA procedure. High‐ICOS expression in urine was associated with a higher post‐void residual and a lower maximum urinary flow rate. CONCLUSIONS Four genes were significantly upregulated at the mRNA level in the prostate tissue of patients with severe inflammation score. Two proteins were measured in urine samples, and were associated with maximum uroflowmetry and post‐void residual. A prospective clinical study is needed to confirm their clinical relevance. Prostate 71:1701–1709, 2011. © 2011 Wiley‐Liss, Inc.